U.K. startup CellVoyant debuts AI platform that could radically reduce the cost of cell-based therapies such as CAR-T immunotherapy for cancer
CellVoyant says its FateView platform can reduce the cost of producing viable cells for cell-based therapies by up to 80%
(Fortune, 2025-12-18T12:47:48Z)